AN2 Therapeutics, Inc. ANTX
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- +266.67%
- 1 year
- +263.48%
- Market cap
- 157.74M
- EPS (ttm)
- -1.05
- Shares out
- 29.88M
- Forward P/E
- -1.17
- YTD return
- +266.67%
- 1-year return
- +263.48%
- Volume
- 160.40K
- Avg volume
- 261.76K
- Open
- 4.38
- Previous close
- 4.35
- Day's range
- 4.10 – 4.55
- 52-week range
- 1.00 – 7.19
- Beta
- -0.22
- Price target
- 2.67 (-36.2%)
- Earnings date
- Aug 13, 2024
1m -0.19 (-4.19%)
Key statistics
- Enterprise value
- -74.70M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -36.40M
- Total cash
- 104.54M
- Total debt
- 0
- Return on equity
- -69.48%
- Short % of float
- 0.69%
- 50-day average
- 1.22
- 200-day average
- 1.88
Analyst view
- Target (low)
- 1.00
- Target (mean)
- 2.67
- Target (high)
- 5.00
- Strong buy1
- Buy0
- Hold3
- Sell1
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.26.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.37 | -0.43 | -0.06 | -16.22% |
| Aug 13, 2024 | Jun 1, 2024 | -0.63 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -0.63 | -0.48 | +0.15 | +23.81% |
| May 14, 2024 | Mar 1, 2024 | -0.61 | -0.56 | +0.05 | +8.20% |
| May 14, 2024 | Mar 1, 2024 | -0.61 | — | — | — |
| Mar 28, 2024 | Dec 1, 2023 | -0.71 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Nov 18, 2024 | TD Cowen | down | Buy | Hold |
| Aug 9, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| Jul 3, 2024 | Leerink Partners | up | Market Perform | Outperform |
| May 16, 2024 | Evercore ISI Group | main | In-Line | In-Line |
| Apr 2, 2024 | JMP Securities | up | Market Perform | Market Outperform |
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- an2therapeutics.com
News
AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera 
AN2 Therapeutics To Reveal Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera At The SOHO 2026 Annual Meeting 
QUICK SPARK: Russell 2000 Hits New Record Highs, Beats Nasdaq 100 In 2026 
AN2 Therapeutics Q2 EPS $(0.18) Beats $(0.27) Estimate 
Guggenheim Initiates Coverage On AN2 Therapeutics with Buy Rating, Announces Price Target of $9 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
AN2 Therapeutics Announces Results From Two Studies Evaluating Its Oral CPSF3 Inhibitor, AN2-502998, For The Treatment Of Chronic Chagas Disease; Parasites Eliminated With 28-Day Treatment In 100% Of Nonhuman Primates 
AN2 Therapeutics Announces Results From Two Studies Evaluating Oral CPSF3 Inhibitor, AN2-502998, For Treatment Of Chronic Chagas Disease Caused By Infection With Parasite T. Cruzi - Leerink Partners Upgrades AN2 Therapeutics to Outperform, Announces $9 Price Target
12 Health Care Stocks Moving In Friday's Pre-Market Session
Your note
Sign in to keep a note on ANTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHANDA SANJAY | Officer | Stock Award(Grant) | Mar 14, 2024 | 28,235 |
| DAY LUCY O. | Chief Financial Officer | Stock Award(Grant) | Mar 14, 2024 | 30,627 |
| EASOM ERIC | Chief Executive Officer | Purchase | Nov 17, 2024 | 0 |
| ECKBURG PAUL | Officer | Stock Award(Grant) | Mar 14, 2024 | 51,416 |
| EIZEN JOSHUA M | Chief Operating Officer | Stock Award(Grant) | Nov 3, 2024 | 126,335 |
| KRAUSE KEVIN MICHAEL | Officer | Stock Award(Grant) | Mar 14, 2024 | 31,914 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BML Capital Management, LLC | 19.24% | 5,749,432 | 7.82M | Sep 29, 2024 |
| RA Capital Management, L.P. | 6.69% | 1,999,997 | 2.72M | Sep 29, 2024 |
| TCG Crossover Management, LLC | 5.20% | 1,555,118 | 2.11M | Sep 29, 2024 |
| Vanguard Group Inc | 3.49% | 1,041,527 | 1.42M | Sep 29, 2024 |
| Acuitas Investments LLC | 1.49% | 445,783 | 606.26K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.42% | 423,800 | 576.37K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.51% | 749,421 | 1.02M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.88% | 261,931 | 356.23K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.54% | 161,300 | 219.37K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.40% | 119,262 | 162.20K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.12% | 35,457 | 48.22K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 0.11% | 33,200 | 45.15K | Sep 29, 2024 |